Breaking Research News from sources other than Breastcancer.org
Comments
-
Warmer Climate Tied to Favorable Breast Cancer Outcomes
Higher environmental temperatures are associated with better outcomes (significant improvements in pCR as well as OS) among patients with stage I-III breast cancer, according to research presented in a poster at the NCCN 2022 Annual Conference.
0 -
onmagosh... debbew.... your post made my day. Is this an excuse to spend the winter in a warm climate? (Access to care issues aside)
I am such a wimp about the cold and by this time of year, I am ready to petition for no more winter! Now I have a therapeutic excuse. Love it! 0 -
Lumpie, debbew, & moth:
Thanks for keeping this thread active and informing the community on all the research that's out there. This is such a helpful thread
0 -
Lumpie, I was quite surprised to see that article, too! I wondered if it had anything to do with vitamin D, but that doesn't seem to be what they are thinking.
Norcals, thanks for the nod! Lumpie has led the way but I'm always interested to see what all the other posters have uncovered.
0 -
debbew That's great news! I went through all my treatments, surgery during the hottest Florida months May - September
0 -
timing of chemo - as in morning or afternoon- may affect outcomes
"patients who received most treatments after noon required fewer dose reductions and were less likely to stop treatment.
In addition, recurrence rates were highest among patients who received at least 70% of treatments before noon."
https://www.cancertherapyadvisor.com/home/news/con...
0 -
test
0 -
test
0 -
Cardamonin shows promise for treating aggressive breast cancer
Study shows that compound from cardamom spice can kill triple-negative breast cancer cells
0 -
Hepatic Resection for Breast Cancer–Related Liver Metastases
Published in Metastatic Breast Cancer
Journal Scan / Research · April 11, 2022
- This retrospective study from a single institution described the outcomes of patients undergoing liver resection for breast cancer–related liver metastases and identified any clinicopathological variables associated with recurrence or survival. The findings showed that among 20 patients with breast cancer–associated liver metastases, hepatic resection was associated with a median disease-free survival of 50 months and a 5-year OS of 65%.
- {A} Few patients may benefit from hepatic resection for breast cancer–related liver metastases and this approach appears to be feasible and safe.
- CONCLUSIONS: This study has demonstrated that liver resection for breast cancer-related liver metastases is feasible, safe and associated with prolonged disease free and overall survival in selected patients. It is likely that this option will be offered to more patients going forward, however, the difficulty lies in selecting out those who will benefit from liver resection particularly given the increasing number of systemic treatments and local ablative methods available that offer good long-term results.
{Summary, abstract and full article all appear to be free of charge.}0 -
Hi All, been a while since the crash and just catching up.
I've had some progression and my MO is suggesting Vinorelbine as next step. However I can't find ANYTHING positive about this drug…apart from it being effective in a mouse trial ina combo to tackle brain mets. It's old, it doesn't seem to be particularly effective and has been 'relegated' to later stage treatment. Does anyone have anything positive on this drug to share?0 -
karenfizedbo15, I am so sorry to hear about your progression and concern over drugs. I have taken Vinorelbine. I was on the Aviator trial and got Group B: Trastuzumab + Vinorelbine + Avelumab. It did not help me and I "progressed" off of it really quickly. Sorry that is probably not very encouraging. It looks to me like the trial is still recruiting (https://clinicaltrials.gov/ct2/show/NCT03414658) so it must be working for some people. You might check out the trial. Looks like you are triple + so IDK if that fits with their recruitment. I don't recall it being particularly hard to tolerate. I do think I lost my hair, but that sort of goes with the territory at this point. Next I was on Kadcyla, as part of the DS-8201 clinical trial (control arm), and it did not work for long for me and had some ugly side effects. Then we irradiated my brain and liver (Cyberknife) and I went on DS-8201/Enhertu. The combo has kept things under control thus far. Sure hope you find some thing that is tolerable and works well for you!
0 -
Thanks Lumpie! I’m ER+ and HER2+. You story seems to be the norm, that I can find. Checked the trial link but it’s showing an error. It is encouraging that you’ve managed to find SOMETHING to keep you stable though!
0 -
Thanks, karenfizedbo15. In case you or any others readers are searching, the Aviator trial is: ClinicalTrials.gov Identifier: NCT03414658. Yes, anything to keep us stable. Thankfully, lots of people having luck on Enhertu. It has some challenging SE's, but for a lot of people, it works. Good luck!
0 -
I see this thread is a bit quieter... let's revive it! Some very good news on TDX-D for her2low (IHC +1/+2): https://www.onclive.com/view/fda-grants-breakthrou...
Saulius
0 -
Interesting in-animal study for cyclophosphamide+CSF1R-inhibitor in mTNBC. Some macrophages inhibition mechanisms... Hope such things come into clinical trials sooner than later: https://scienmag.com/a-promising-combination-thera...
Saulius
0 -
With some of these articles, I need Cliff Notes For Dummies, if there is such a thing!
0 -
Dear Homemom, Cliff Notes for Dummies would be useful for me too:)D I also sometimes feel they write these articles only for a few selected people - nothing has changed since times of Socrates:)
Saulius
0 -
NUS scientists develop painless way to shrink breast cancer using magnetic fields
https://www.straitstimes.com/singapore/health/nus-...
0 -
The most detailed photograph of a cell inner: https://angstrom3d.com/cst-molecular-landscapes
Man... how complicated life really is:/
Saulius
0 -
Observing ESMO: extremely interesting results in mTNBC BEGONIA clinical trial: 1st line Durvalumab+Dato_DXd = 74% ORR irrespective of PD-L1 status. Amazing!
0 -
I’m wondering if anyone has an article or info on the efficacy of full axillary node removal vs radiation of nodes after a positive frozen section of the Sentinal node in surgery, but specifically for those with tumors over 5cm treated with neoadjuvent chemo. I can’t find info on this subset, most articles talk about small tumors and/or don’t mention neoadjuvent chemo.
Thanks in advance
0 -
Dear xfitmama2, can you highlight your diagnosis/histologies/history as decisions are made depending on them? Standard of care could be easily found in ESMO guidelines but I believe you are familiar with them. The discussion in this sphere (LN removal, Sentinel removal, radiation vs removal, mastectomy/lumpectomy&nod removal) is still going on, you can find come comparison studies but I'd be surprised if you found such a comparison for that exact subset.
Saulius
0 -
Researchers reveal a possible biological mechanism connecting breast cancer and type 2 diabetes
https://www.news-medical.net/news/20220530/Researc...
0 -
Ultrasound-guided microbubbles boost immunotherapy efficacy
...In the preclinical study, the MUSIC strategy demonstrated a complete tumor eradication rate of 60% when administered as monotherapy in breast cancer models...
https://www.sciencedaily.com/releases/2022/05/2205...
1 -
Cancer-killing virus injected into human for the first time in new clinical trial
Previous studies have shown that CF33-hNIS is effective against cell culture and animal models of breast, colorectal, pancreatic, ovarian, and lung cancers. During the Phase 1 clinical trial, researchers will test the safety and tolerability of CF33-hNIS in cancer patients by injecting the virus directly into the blood or the tumor.
0 -
'Masked' Cancer Drug Kills Tumors While Sparing Healthy Tissue, Early Results Show
In breast cancer models, our masked IL-12 resulted in a 90 percent cure rate, while treatment with a commonly used immunotherapy called a checkpoint inhibitor resulted in only a 10 percent cure rate.
https://www.sciencealert.com/masked-cancer-drug-ki...
0 -
New Biomarker Classifications May Improve Treatment for High-Risk Breast Cancer Patients
The researchers, whose findings were recently published online in Cancer Cell, show that by combining predictive biomarkers to create response predicting breast cancer subtypes, these subtypes can then be matched to the most effective modern treatments. The best subtyping schemas incorporate Immune, DNA repair, Luminal, and HER2 phenotypes, Treatment assignment using these response predictive subtypes may improve the efficacy of the treatment and patient outcomes.
https://www.ucsf.edu/news/2022/06/423061/new-bioma...
0 -
ASCO: AstraZeneca, Daiichi's Enhertu could transform breast cancer treatment with landmark HER2-low show
At a median follow-up of 18.4 months, Enhertu extended the median time patients had lived without disease worsening to 9.9 months, versus 5.1 months for patients who got physician's choice of chemotherapy. The drug prolonged patients' lives to a median of 23.4 months, compared with 16.8 months for chemo, according to data presented at a plenary session of the 2022 American Society of Clinical Oncology annual meeting.
https://www.fiercepharma.com/pharma/asco-astrazene...
0 -
Thanks, Debbrew- interesting articles
0
